NCT05565768View on ClinicalTrials.gov

Study to Evaluate HZN-457 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 22, 2022

Primary Completion Date

August 9, 2023

Study Completion Date

August 9, 2023

Conditions
Healthy
Interventions
DRUG

HZN-457

HZN-457 will be given in one subcutaneous administration

DRUG

Placebo

Placebo will be given in one subcutaneous administration

Trial Locations (2)

Unknown

New Zealand Clinical Research, Auckland

New Zealand Clinical Research, Christchurch

Sponsors
All Listed Sponsors
lead

Horizon Therapeutics Ireland DAC

INDUSTRY